期刊文献+

子痫前期患者血清及胎盘激活素A水平变化的研究 被引量:1

The changing concentration of serum and placenta activin A in preeclampsia
原文传递
导出
摘要 目的 研究子痫前期患者血清及胎盘激活素A水平的变化及其与病情的关系。方法 采用ELISA检测40例子痫前期患者(子痫前期组,包括20例轻度,20例重度)和40例健康晚孕期妇女(正常妊娠组)的血清激活素A的水平;采用免疫组化方法检测胎盘激活素A的水平。结果 子痫前期组血清、胎盘激活素A水平分别为(32.23±6.11)μg/L、(516.14±5.46)μg/L,明显高于正常妊娠组的(8.04±2.19)μg/L、(275.38±18.12)μg/L(P〈0.01);其中重度子痫前期患者血清、胎盘激活素A水平较轻度子痫前期患者升高(P〈0.01);子痫前期组血清、胎盘激活素A水平与24h尿蛋白含量之间呈显著正相关;重度子痫前期伴胎儿生长受限(FGR)者血清胎盘激活素A水平较不伴FCR者差异均无统计学意义(P〉0.05)。结论 子痫前期患者血清、胎盘激活素A水平较健康晚孕期妇女显著升高,且与子痫前期病情进展关系密切。 Objective To investigate the alteration of serum and placenta activin A in women with preeclampsia,and study the relationship of them and pathogenetic condition. Methods The serum level and the placenta expression of activin A were assayed in 40 women with preeclarnpsia (preeclampsia group, 20 patients with mild preeclampsia and another 20 with severe preeclampsia) and 40 normal pregnant women (normal pregnant group) by specific ELISA and histochemistry. Results The serum and placenta concentrations of activin A were significantly higher in the preeclampsia group (32.23 ± 6.11 )μ g/L, (516.14 ± 5.46) μ g/L, than those in the normal pregnant group (8.04 ± 2.19)μ g/L, (275.38 ± 18.12)μ g/L (P 〈 0.01 ). Compared with patients of the mild preeclampsia, the serum and placenta activin A of the severe preeclampsia were significantly higher (P 〈 0.01 ), and activin A levels were significantly correlated with the 24-hour proteinuria levels in the preeclampsia group. The serum and placenta activin A in the severe preeclampsia with fetal growth retardation (FGR) had no significant difference compared with those without FGR (P 〉 0.05 ). Conclusion Serum levels and the placenta expression of activin A are significantly increased in women with preeclampsia, and they are correlated with the degree of severity of the disease.
出处 《中国医师进修杂志》 2008年第1期27-29,共3页 Chinese Journal of Postgraduates of Medicine
关键词 子痫前期 激活素A Preeclampsia Activin A
  • 相关文献

同被引文献16

  • 1陈晖.重度妊娠高血压综合征合并胎儿生长受限的围生儿结局分析[J].中国医药,2006,1(5):310-311. 被引量:6
  • 2贾金平.292例胎儿生长受限相关危险因素分析[J].中国基层医药,2006,13(8):1288-1290. 被引量:2
  • 3Kim YN, Lee DS, Jeong DH, et al. The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia. Prenat Diagn,2009,20 (5) :464-470.
  • 4Venkatesha S, Toporsian M, Lain C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med, 2006,12 (6) :642-649.
  • 5Staff AC, Braekke K, Johnsen GM, et al. Circulating concentra tions of soluble endoglin( CD105 ) in fetal and maternal serum and in amniotic fluid in preeclampsia. Am J Obstet Gynecol,2007,197 (2) :e1-e6.
  • 6Kanaka-Gantenbein C, Mastorakos G, Chrousos GP. Endocrine-related causes and consequences of intrauterine growth retardation. Ann N Y Acad Sci, 2003, 997:150-157.
  • 7Bischof P, Meisser A, Campana A. Paracrine and autocrine regulators of trophoblast invasion--a review. Placenta,2000,21 Suppl A : 55-60.
  • 8Jeyabalan A, McGonigal S, Gilmour C, et al. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta, 2008,29(6) : 555-563.
  • 9Stepan H, Kraer T, Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab, 2007,92(7) :2831-2834.
  • 10Gilbert JS, Gilbert SA, Arany M ,et al. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension,2009,53 ( 2 ) : 399 -403.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部